Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Amarin Corporation (AMRN) stocks in Canada

Learn how to easily invest in Amarin Corporation stocks.

Amarin Corporation is a biotechnology business based in the US. Amarin Corporation stocks (AMRN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.47 – an increase of 7.49% over the previous week. Amarin Corporation employs 1,000 staff and has a trailing 12-month revenue of around $605.9 million.

How to buy shares in Amarin Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AMRN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Amarin Corporation stock price (NASDAQ:AMRN)

Use our graph to track the performance of AMRN stocks over time.

Amarin Corporation shares at a glance

Information last updated 2022-01-23.
Latest market close$3.30
52-week range$3.04 - $9.25
50-day moving average $3.54
200-day moving average $4.52
Wall St. target price$9.31
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.01

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Amarin Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Amarin Corporation price performance over time

Historical closes compared with the close of $3.3 from 2022-01-27

1 week (2022-01-21) 7.49%
1 month (2021-12-28) -3.23%
3 months (2021-10-28) -29.34%
6 months (2021-07-28) -22.90%
1 year (2021-01-28) -54.79%
2 years (2020-01-28) -83.71%
3 years (2019-01-28) 16.87
5 years (2017-01-27) 12.24%

Is Amarin Corporation under- or over-valued?

Valuing Amarin Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amarin Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Amarin Corporation's EBITDA

Amarin Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $18.2 million.

The EBITDA is a measure of a Amarin Corporation's overall financial performance and is widely used to measure a its profitability.

Amarin Corporation financials

Revenue TTM $605.9 million
Operating margin TTM 2.58%
Gross profit TTM $482.6 million
Return on assets TTM 0.98%
Return on equity TTM -0.33%
Profit margin -0.34%
Book value $1.62
Market capitalisation $1.2 billion

TTM: trailing 12 months

Amarin Corporation share dividends

We're not expecting Amarin Corporation to pay a dividend over the next 12 months.

Have Amarin Corporation's shares ever split?

Amarin Corporation's shares were split on a 1:10 basis on 17 January 2008. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Amarin Corporation shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Amarin Corporation shares which in turn could have impacted Amarin Corporation's share price.

Amarin Corporation share price volatility

Over the last 12 months, Amarin Corporation's shares have ranged in value from as little as $3.04 up to $9.25. A popular way to gauge a stock's volatility is its "beta".

AMRN.US volatility(beta: 2.14)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amarin Corporation's is 2.1389. This would suggest that Amarin Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Amarin Corporation overview

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co. , Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site